Alli and kidney stones: what FDA changed in the OTC warning
FDA added kidney-stone and kidney-injury information to OTC alli labeling in June 2026. The decision drew on rare postmarketing reports, which cannot establish how often an event occurs.
FDA approved a new kidney-stone and kidney-injury warning for OTC alli (orlistat) in June 2026. The agency reviewed 12 postmarketing cases, including reports of oxalate-related kidney injury and calcium-oxalate stones. Those reports justify a warning but do not tell a person the event’s frequency or prove that every stone after alli was caused by the drug. The OTC label flags a prior kidney-disease or stone history for clinician review.12
If back or groin pain, painful urination, blood in the urine, swelling of the feet or legs, or less frequent urination is happening now, contact a clinician promptly. FDA names these as symptoms to discuss with a doctor; an article cannot determine their cause.1
The change is more specific than a general OTC versus prescription weight-care comparison. It updates a named Drug Facts question: what does a person with a stone history need to know about this particular over-the-counter product? Orlistat’s mechanism and evidence should not be confused with Qsymia’s topiramate-associated stone warning or a GLP-1 trial signal.
What FDA actually counted
FDA’s June communication describes 12 case reports from 2007 through 2023, drawn from adverse-event reporting and medical literature. The reports included acute kidney injury, oxalate nephropathy or hyperoxaluria, and calcium-oxalate kidney stones. A case report is a signal: it describes a suspected association that merits scrutiny. The total does not include a known denominator of all exposed users or a controlled comparison, so 12 is not a rate and cannot be turned into a personal percentage.1
The OTC label asks people with a history of kidney disease or kidney stones to speak with a doctor before use. That is a label-based handoff, not a rule that a website can use to determine whether the prior event was oxalate-related or whether a specific plan is appropriate. A clinician may need the earlier diagnosis and tests to interpret the warning in context.2
| Evidence item | Supports | Does not support |
|---|---|---|
| FDA warning decision | Kidney injury and stones belong in consumer labeling | A measured event frequency in all users |
| Twelve suspected cases | A plausible safety signal worth review | Proof of cause in every report |
| Prior-stone Drug Facts question | Bring history to a clinician | An online diagnosis of stone type or suitability |
Keep the competing product signals separate
Qsymia has a topiramate-related nephrolithiasis mechanism and trial rates in its own label. The GLP-1 kidney-stone article interprets a different study record. These cannot be collapsed into a single “weight drugs cause stones” statistic. Even OTC and prescription orlistat have different package strengths and label contexts, so the product being considered should be named precisely.12
For a weight-care visit, bring the exact alli package, any earlier stone-analysis or kidney diagnosis, other medicines, and the reason for considering OTC treatment. Ask the clinician what the new warning means for that record and how other weight-management options compare. Find a medical weight-management service that reviews OTC exposures as part of the medication history, not only prescriptions.
What changed on the shelf and what did not
The FDA communication concerns the OTC alli labeling, bringing kidney information into the consumer-facing Drug Facts record. That change does not mean FDA newly discovered 12 events in June 2026; the agency reviewed reports spanning years. It also does not establish that alli was previously proven free of kidney risk. A label update changes what a buyer can see and discuss, while the evidence underneath remains postmarketing reports with all their uncertainty.1
One important detail is that several reported outcomes are not interchangeable. An oxalate kidney stone is a material finding; oxalate nephropathy concerns kidney tissue injury; acute kidney injury describes a change in kidney function. The FDA communication groups related cases for a safety warning, not because every one followed the same clinical pathway. A history of one outcome does not let an online article infer the others. The current OTC label’s prior-kidney-history question is deliberately broader than a single stone type.12
A credible interpretation of a low-count report
Postmarketing reports are valuable for finding uncommon signals that preapproval trials may not reveal. But reporting is incomplete and selective, and a submitted case can have competing causes. Without a reliable count of exposed users and a comparison group, neither “12 in many years means negligible risk” nor “12 cases prove high risk” follows. FDA’s regulatory choice is to give consumers and clinicians an explicit warning and a place to discuss prior kidney history.1
For a practice, that means documenting the exact OTC product alongside prescriptions. For a reader, it means resisting a false precision claim from a store shelf or a social post. Ask which evidence supports the risk statement, whether it is a controlled study or a spontaneous-report review, and what part of the existing medical record matters to the proposed decision. This narrow interpretation is the information gain beyond a general comparison of OTC and prescription weight care.
Sources
- U.S. Food and Drug Administration. FDA approves alli OTC labeling changes for kidney stones and kidney injury. June 10, 2026 communication describes the warning and 12 postmarketing cases without an incidence estimate. Accessed .
- National Library of Medicine DailyMed. alli orlistat 60 mg Drug Facts. OTC label asks consumers with past kidney disease or stones to speak with a doctor before use. Accessed .